Been looking at the gene editing space lately and stumbled on something worth thinking about. Everyone talks about CRISPR Therapeutics when gene editing comes up, but honestly? The real play might already be sitting right in front of us.

So here's the thing. CRISPR got famous for Casgevy, that Nobel Prize-winning breakthrough medicine that hit the market in 2023. It treats sickle cell disease and transfusion-dependent beta-thalassemia. Revolutionary stuff, no question. But here's where it gets interesting - Casgevy is basically CRISPR's only shot right now. That's the entire revenue story.

Now I get why people get excited about it. Gene editing therapies could genuinely transform how we treat diseases. The upside is real. But Casgevy's commercial reality? It's complicated. The treatment costs $2.2 million per course in the US, requires specialized treatment centers, and involves this complex cell collection and modification process. Insurance companies are naturally hesitant. So despite being revolutionary, it's generating minimal revenue and CRISPR keeps posting losses.

Then you've got Vertex Pharmaceuticals. Most people don't think of them as a pure gene editing player, but that's exactly why they're interesting. Vertex partnered with CRISPR on Casgevy, sure, but that's just one piece of their portfolio. They've got a whole lineup of products actually generating consistent profits and revenue right now. Casgevy is almost a bonus for them.

The difference matters. If you're the type who loses sleep over volatility, CRISPR could absolutely wreck you. Their pipeline has potential - CTX310 for LDL cholesterol and lipoprotein(a) could be genuinely transformative if it clears trials. But if those candidates stumble, the stock gets hit hard. It's all or nothing energy.

Vertex? Different beast entirely. Yeah, they don't have the same moonshot potential as CRISPR. But they've got the stability to absorb setbacks. They've got multiple mid and late-stage candidates that should see approvals within the next few years. Gene editing exposure without putting all your eggs in that one basket.

That's the real insight here. Gene editing is still early, still figuring out adoption and reimbursement. CRISPR might explode if everything goes right. But Vertex gives you exposure to gene editing breakthroughs while actually having a business that works today. For most investors, that's probably the smarter move.